PIRAMAL PHARMA
|
|
| BOM : 543635 NSE : PPLPHARMA | |
| LT :
Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
May 30,2025 |
|
Price(EOD): ₹ 206.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 27,421.40 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| PIRAMAL PHARMA | 0.5% | -2.3% | 37% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.2% | -8.3% | 15.9% |
| DIVIS LABORATORIES | -1.9% | 8.6% | 55.9% |
| CIPLA | -1.3% | -5.5% | -0.1% |
| TORRENT PHARMACEUTICALS | -0.5% | -4.2% | 19.3% |
| DR REDDYS LABORATORIES | 0.7% | 5.8% | 6.1% |
| MANKIND PHARMA | 1.8% | 0.4% | 16.6% |
| ZYDUS LIFESCIENCES | 1.9% | 4.8% | -12.7% |
| LUPIN | -1.5% | -6.5% | 21.9% |
FUNDAMENTAL ANALYSIS OF PIRAMAL PHARMA
[ Q(TTM): Mar2025, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF PIRAMAL PHARMA
[As on : May 30,2025
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
1506.72
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 18.20 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] 3.37
P/B Calculated based on Book Value of Rs 8,125.47 Cr
[Latest Year - Mar2025 - Consolidated Results ] 3
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 9,151.18 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
237% 218% 69% |
SHARE PRICE MOMENTUM OF PIRAMAL PHARMA
PIRAMAL PHARMA vs SENSEX
DEBT OF PIRAMAL PHARMA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2024 2023 2022 Avg_3yrs |
0.17 0.31 0.23 0.24 |
0.58 0.81 0.6 0.66 |
|
[Last Annual Data : Mar2024]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF PIRAMAL PHARMA
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF PIRAMAL PHARMA
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
24.95% 66.1% 415.74% 1126.78% |
7.9% 5.86% 19.1% 53.85% |
| QtrlyTrend |
8 | |
| Latest Qtr: Mar2025 | ||
| Quarterly Result Analysis → | ||
PIRAMAL PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE SMALLCAP | 1.7% | 8.7% | 9.2% |
| BSE SMALLCAP SELECT INDEX | 1.5% | 7.3% | 8.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY ALPHA 50 | 2.1% | 6.1% | -4.4% |
| NIFTY SMALLCAP 250 | 1.8% | 7.6% | 6.1% |
| NIFTY MIDSMALLCAP 400 | 1.4% | 6.3% | 7.3% |
| NIFTY SMALLCAP 100 | 1.4% | 6.8% | 5.9% |
| NIFTY 500 EQUAL WEIGHT | 1.3% | 7.2% | NA |
You may also like the below Video Courses
FAQ about PIRAMAL PHARMA
Is PIRAMAL PHARMA good for long term investment?
As on May 30,2025, the Fundamentals of PIRAMAL PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of PIRAMAL PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is PIRAMAL PHARMA UnderValued or OverValued?
As on May 30,2025, PIRAMAL PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of PIRAMAL PHARMA ?
As on May 30,2025, the Intrinsic Value of PIRAMAL PHARMA is Rs. 64.81 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 61.19
Fair Value [Median EV / Sales Model] : Rs. 64.81
Fair Value [Median Price / Sales Model] : Rs. 122.16
Estimated Median Fair Value of PIRAMAL PHARMA : Rs. 64.81
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
